8-K: Cingulate Inc. Reports Q3 2026 Results, Delays NDA Resubmission

Cingulate Inc. announced third quarter 2026 financial results, reporting substantial completion of manufacturing work for CTx-1301 and an expected NDA resubmission between December 2026 and January 2027, while also noting increased operating expenses.

Summary

• Cingulate Inc. reported its financial results for the third quarter ended September 30, 2026.
• The company has substantially completed manufacturing work to address FDA CMC information requests for CTx-1301.
• The New Drug Application (NDA) resubmission for CTx-1301 is now expected between December 2026 and January 2027.
• As of September 30, 2026, Cingulate had $23.2 million in cash and cash equivalents, with sufficient funds projected into mid-2027.
• Research and development expenses for Q3 2026 were $2.9 million, a slight increase from the prior year.
• Selling, general, and administrative (SG&A) expenses increased significantly by 45.5% to $4.6 million in Q3 2026 compared to Q3 2025.
• The net loss for Q3 2026 was $7.7 million, a slight increase from $7.3 million in Q3 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment due to the delay in NDA resubmission and increased operating expenses, despite positive progress on manufacturing.

Positives

• Substantially completed manufacturing work to address FDA CMC information requests for CTx-1301.
• The FDA's Complete Response Letter did not raise concerns about the clinical safety or efficacy of CTx-1301.
• Cash and cash equivalents increased to $23.2 million as of September 30, 2026, from $11.0 million at the end of 2025.
• Working capital increased to $18.8 million as of September 30, 2026, from $1.7 million at the end of 2025.
• The company believes its current cash position is sufficient to fund operations into mid-2027.

Negatives

• The NDA resubmission for CTx-1301 has been delayed and is now expected between December 2026 and January 2027.
• Selling, general, and administrative (SG&A) expenses increased by 45.5% in Q3 2026 compared to Q3 2025.
• Net loss for the third quarter of 2026 was $7.7 million, an increase from $7.3 million in the same period of 2025.
• For the nine months ended September 30, 2026, SG&A expenses increased by 116.6% compared to the same period in 2025.

Risks

• There can be no assurance regarding the timing of any resubmission or whether approval will occur.
• Actual results may differ materially from forward-looking statements due to various factors disclosed in SEC filings.
• The company's ability to continue as a going concern is dependent on its ability to secure additional financing and achieve profitability.

Future Outlook

The company expects to resubmit the NDA for CTx-1301 between December 2026 and January 2027. Following resubmission, the FDA is expected to classify it as a Class 1 (2-month review) or Class 2 (6-month review). The company believes its current cash and cash equivalents are sufficient to fund operations into mid-2027.

Management Comments

• "With the manufacturing work substantially complete, we are now finalizing the data and documentation needed to resubmit the NDA for CTx-1301, and we expect to do so by January 2027, potentially sooner," stated Cingulate Chairman and CEO Shane J. Schaffer.
• "Importantly, the FDAs Complete Response Letter did not raise any concerns about the clinical safety or efficacy of CTx-1301. We thank our shareholders for their patience and continued support as we work to bring this treatment to patients with ADHD."

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry, particularly in the ADHD space, is highly competitive and subject to rigorous regulatory scrutiny. Delays in FDA submissions and approvals are common, and companies often need to raise significant capital to fund development and commercialization. Cingulate's progress on manufacturing for CTx-1301 is a positive step, but the extended timeline for resubmission and increasing SG&A expenses are areas of concern.

Comparison to Industry Standards

• The estimated US ADHD market represents approximately 100 million annual prescriptions.
• The FDA review goals for resubmitted NDAs are typically 2 months for Class 1 and 6 months for Class 2, indicating a potential review period for CTx-1301 post-resubmission.
• Companies in the biopharmaceutical sector often experience significant increases in SG&A expenses as they build commercial readiness capabilities, as seen with Cingulate's partner Indegene.

Stakeholder Impact

• Shareholders: Potential dilution from ongoing ATM facility usage, but also potential upside if CTx-1301 is approved. Patience is requested due to delays.
• Patients: Continued delay in potential access to CTx-1301 for ADHD treatment.
• Creditors/Suppliers: Increased SG&A and R&D expenses may impact short-term cash flow, but current cash position is projected to cover operations into mid-2027.

Next Steps

• Finalize data and documentation for CTx-1301 NDA resubmission.
• Resubmit the NDA for CTx-1301 between December 2026 and January 2027.
• Prepare for FDA review of the resubmitted NDA (expected Class 1 or Class 2 review).
• Continue build-out of commercial readiness capabilities.
• Monitor cash runway and potential future financing needs.

Key Dates

Recommendation

The company has made progress on manufacturing for CTx-1301, and its cash position is adequate into mid-2027. However, the delay in NDA resubmission, increased operating expenses, and the inherent risks in biopharmaceutical development warrant a cautious 'hold' rating. Further clarity on the FDA review timeline and commercialization strategy will be crucial.

Keywords

CTx-1301, NDA resubmission, ADHD treatment, biopharmaceutical, CMC, FDA, Precision Timed Release, financial results